Transistor (https://transistor.fm) https://feeds.transistor.fm/modality-matters Welcome to Clinical Trial Insights and Innovation, the interview series where we talk to experts in medical research. Each episode features conversations with professionals who are actively involved in designing, conducting, and analyzing clinical studies. Our goal is to provide insights into the process, challenges, and latest developments in clinical trials and research studies. Subscribe now. © Modality.AI 77eb0d51-fe1c-55c4-a32d-44628b71ece2 yes David Suendermann-Oeft en Sat, 07 Jun 2025 22:12:00 -0700 Fri, 06 Mar 2026 09:10:35 -0800 https://modality.ai https://img.transistorcdn.com/NNiWFw8V0-Hr3lj3i6AgSrKfh2Isr8YxXjtRdHDYa3s/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS8yYjM3/MDQ5MTI4YWYzYmMy/Y2JjMzNlNTQ3Zjdm/NWU4My5wbmc.jpg https://modality.ai episodic Modality.AI Welcome to Clinical Trial Insights and Innovation, the interview series where we talk to experts in medical research. Each episode features conversations with professionals who are actively involved in designing, conducting, and analyzing clinical studies. Our goal is to provide insights into the process, challenges, and latest developments in clinical trials and research studies. Subscribe now. Welcome to Clinical Trial Insights and Innovation, the interview series where we talk to experts in medical research. Clinical Research, Clinical Trials David Fox No No 1 1 A Turning Point in ALS Trials full 10ca0a55-c7e6-4092-9f97-45a4cabe3252 https://share.transistor.fm/s/8bef0783 To drive a turnaround in trials for ALS and other neurological diseases, we at Modality advocate for new tools that increase understanding of the course of disease and response to treatment. Together with MGH, Everything ALS, and, more recently, Verge Genomics, Modality’s platform is building the most comprehensive audio/visual dataset of people living with ALS. In this 45-minute call, we discuss advancements in digital endpoints in clinical trials and the potential to accelerate clinical research. Our special guest is Karl Kieburtz, MD, MPH, Co-Founder and Chair of Clintrex and principal investigator for numerous multi-center trials in neurology.

]]> To drive a turnaround in trials for ALS and other neurological diseases, we at Modality advocate for new tools that increase understanding of the course of disease and response to treatment. Together with MGH, Everything ALS, and, more recently, Verge Genomics, Modality’s platform is building the most comprehensive audio/visual dataset of people living with ALS. In this 45-minute call, we discuss advancements in digital endpoints in clinical trials and the potential to accelerate clinical research. Our special guest is Karl Kieburtz, MD, MPH, Co-Founder and Chair of Clintrex and principal investigator for numerous multi-center trials in neurology.

]]> Sun, 20 Oct 2024 22:18:55 -0700 Modality.AI Modality.AI 2671 To drive a turnaround in trials for ALS and other neurological diseases, we at Modality advocate for new tools that increase understanding of the course of disease and response to treatment. Together with MGH, Everything ALS, and, more recently, Verge Genomics, Modality’s platform is building the most comprehensive audio/visual dataset of people living with ALS. In this 45-minute call, we discuss advancements in digital endpoints in clinical trials and the potential to accelerate clinical research. Our special guest is Karl Kieburtz, MD, MPH, Co-Founder and Chair of Clintrex and principal investigator for numerous multi-center trials in neurology.

]]> Clinical Research, Clinical Trials No David Suendermann-Oeft Karl Kieburtz, MD